InMed Pharmaceuticals (INM) Capital Expenditures (2019 - 2024)

InMed Pharmaceuticals (INM) posted quarterly Capital Expenditures of $14201.0 for Q1 2024, up 893.35% quarter-over-quarter from -$1790.0 in Q4 2023.

InMed Pharmaceuticals (INM) Capital Expenditures (2019 - 2024) Analysis & Trends

InMed Pharmaceuticals' Capital Expenditures history runs 6 years deep, the most recent figure standing at $14201.0 for Q1 2024.

In Q1 2024, Capital Expenditures changed N/A year-over-year to $14201.0; the TTM figure through Jun 2024 stood at $9293.0 (down 94.19% YoY), while the FY2024 annual figure was $9293.0, down 94.19% from the prior year.
Capital Expenditures for Q1 2024 stood at $14201.0, up from -$1790.0 in the prior quarter.
The five-year high for Capital Expenditures was $250000.0 in Q3 2021, with the low at -$256030.0 in Q4 2021.
The 5-year median for Capital Expenditures is -$198.0 (2020), against an average of $17166.9.
Peak annual rise in Capital Expenditures reached 1684.82% in 2021, while the deepest fall reached 166353.25% in 2021.
InMed Pharmaceuticals' Capital Expenditures stood at $154.0 in 2020, then tumbled by 166353.25% to -$256030.0 in 2021, then jumped by 97.85% to -$5507.0 in 2022, then soared by 67.5% to -$1790.0 in 2023, then jumped by 893.35% to $14201.0 in 2024.
Business Quant data shows INM's Capital Expenditures at $14201.0 in Q1 2024, -$1790.0 in Q4 2023, and -$3118.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Haleon	44.07 Bn	43.10 Bn	-	-
2	Teva Pharmaceutical Industries	43.41 Bn	39.75 Bn	2.15 Bn	104.00 Mn
3	Zoetis	31.83 Bn	30.15 Bn	1.05 Bn	117.00 Mn
4	Takeda Pharmaceutical	28.77 Bn	22.97 Bn	5.10 Bn	-337.60 Mn
5	United Therapeutics	22.27 Bn	19.61 Bn	683.80 Mn	108.00 Mn
6	Viatris	18.76 Bn	17.87 Bn	1.46 Bn	52.80 Mn
7	Neurocrine Biosciences	15.65 Bn	15.26 Bn	935.80 Mn	7.80 Mn
8	Elanco Animal Health	11.93 Bn	11.40 Bn	798.00 Mn	33.00 Mn
9	Dr Reddys Laboratories	10.16 Bn	10.00 Bn	-	-
10	InMed Pharmaceuticals	6.56 Mn	1.32 Mn	-	-

Download Data